Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020–2025: a real-world retrospective study from a reference centre
Rheumatology International · 2026
DOI: 10.1007/s00296-026-06173-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology International, 2026. Verfasst von Stylianos Panopoulos und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Programme, Medical School, National and Kapodistrian University of Athe…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Indoles, Scleroderma, Systemic, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Athens.
Abstract (Originalsprache)
Randomized trials have demonstrated that nintedanib is beneficial for Systemic Sclerosis-associated interstitial lung disease (SSc-ILD) with an acceptable safety profile. We evaluated the long-term safety and efficacy of nintedanib in a real-world SSc-ILD cohort. Medical records of SSc patients receiving nintedanib for newly diagnosed fibrotic or progressive ILD between 2020 and 2025 in our center were retrospectively reviewed. Forced vital capacity (FVC%) and diffusing capacity for carbon monoxide (DLCO%), were recorded 12 months before and 12/24/36 months after nintedanib initiation and compared by Wilcoxon signed-rank test. Safety analyses included all treated patients; efficacy analyses excluded patients initiating immunosuppression simultaneously with nintedanib. Fifty-one patients (41 female; 34 diffuse SSc; median age and disease duration of 53 and 6 years, respectively) received nintedanib for a median of 33 months (range 4–60). Diarrhea was the most frequent adverse event leading to dosage reduction in 31% and permanent discontinuation in 14% of patients, respectively. No additional safety signals emerged in patients receiving mycophenolate ( n = 18), tocilizumab ( n = 14), rituximab ( n = 1), mycophenolate plus tocilizumab ( n = 5) or mycophenolate plus rituximab ( n = 2). FVC% and DLCO%, that had declined significantly during the preceding year, remained stable after nintedanib initiation in 23/35 patients with median FVC changes of + 1% and − 3% and median DLCO% changes of -2% and − 4% after 24 and 36 months, respectively), including patients on reduced dosage. Real-world data show that nintedanib seems to stabilize pulmonary function in progressive SSc-ILD, even at reduced doses, during 3 years of follow-up in about half of patients, without safety concerns when combined with biologic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Programme, Medical School, National and Kapodistrian University of Athens, Μedical School General Hospital of Athens ΄΄LAIKO΄΄, 17 Agiou Thom…
Förderung
- University of Athens
Zitieren
APA
Panopoulos, S., Poulia, V., Vlachogiannis, N., Bournia, V. K., Tektonidou, M. G., & Sfikakis, P. P. (2026). Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020–2025: a real-world retrospective study from a reference centre. Rheumatology International. https://doi.org/10.1007/s00296-026-06173-6
Vancouver
Panopoulos S, Poulia V, Vlachogiannis N, Bournia VK, Tektonidou MG, Sfikakis PP. Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020–2025: a real-world retrospective study from a reference centre. Rheumatology International. 2026. doi:10.1007/s00296-026-06173-6
BibTeX
@article{Panopoulos2026,
author = {Panopoulos, Stylianos and Poulia, Vasiliki and Vlachogiannis, Nikolaos and Bournia, Vasiliki-Kalliopi and Tektonidou, Maria G and Sfikakis, Petros P},
title = {Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020–2025: a real-world retrospective study from a reference centre},
journal = {Rheumatology International},
year = {2026},
doi = {10.1007/s00296-026-06173-6}
}
EUVIMED